We are live on
!
Find out more
Tarsus Pharmaceuticals
TARS
TARS
253 hedge funds and large institutions have $3.17B invested in Tarsus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 88 increasing their positions, 82 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 36
31% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $14.6M
3% more funds holding
Funds holding: 246 → 253 (+7)
2.3% more ownership
Funds ownership: 103.77% → 106.07% (+2.3%)
7% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 82
12% less capital invested
Capital invested by funds: $3.61B → $3.17B (-$439M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
253
Holders Change
+7
Holders Change %
+2.85%
% of All Funds
3.11%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
48
Increased
88
Reduced
82
Closed
36
Calls
$19.2M
Puts
$14.6M
Net Calls
+$4.58M
Net Calls Change
-$22.1M
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$41.6M |
| 2 |
Millennium Management
New York
|
+$31.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$30.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$21.7M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$18.6M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$36.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$18.9M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$17.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17M |
| 5 |
BlackRock
New York
|
-$16.6M |
